A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Recruiting · NCT07491497 · Registry updated 2026-09-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC | ALK-Positive Lung Cancer; ALK-positive NSCLC; ALK-positive Non-small Cell Lung Cancer | Recruiting | Phase 1 / Phase 2 | 2026-09-03 | NCT07491497 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| TRIANA Biomedicines, Inc. | 1 |
16 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana Farber Cancer Center | Boston | United States | 6 |
| Duke University | Durham | United States | 1 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| Memorial Sloan-Kettering Cancer Center | New York | United States | 63 |
| NEXT Virginia | Fairfax | United States | 83 |
| Oncology Consultants Research (P1 Trials) | Houston | United States | 1 |
| Peter MacCallum Cancer Centre | Melbourne | Australia | 149 |
| Royal North Shore Hospital | Sydney | Australia | 2 |
| Scri Oncology Partners | Nashville | United States | 156 |
| START-Mountain Region | West Valley City | United States | 1 |
| Taylor Cancer Research Center | Maumee | United States | 24 |
| UCSF | San Francisco | United States | 13 |
| University of Cincinnati Cancer Center | Cincinnati | United States | 1 |
| University of Colorado Cancer Center | Aurora | United States | 63 |
| UPMC Hillman Cancer Center | Pittsburgh | United States | 6 |
| Washington University Medical Center | St Louis | United States | 2 |